Why the study?
Does 99mTc-PYP scintigraphy allow for the noninvasive diagnosis of ATTR cardiac amyloidosis in patients with suspected disease?
Does 99mTc-PYP scintigraphy allow for the noninvasive diagnosis of ATTR cardiac amyloidosis in patients with suspected disease?
99mTc-PYP scintigraphy with SPECT is feasible and effective for the noninvasive diagnosis of ATTR cardiac amyloidosis in a Peruvian clinical setting.
Tc-PYP scintigraphy enabled noninvasive cardiac amyloidosis diagnosis in Peru; leaves open need for larger validation before wider adoption.
Objectives: Tc-PYP scintigraphy in a Peruvian hospital. Materials and Methods: Tc-PYP, planar imaging, and SPECT acquisition at 1 and 3 hours. Noninvasive diagnosis was established in the presence of visual myocardial uptake grade 2-3 (Perugini scale), confirmed by SPECT and after the exclusion of monoclonal plasma cell dyscrasia. The heart-to-contralateral lung (H/CL) ratio was used as a complementary quantitative parameter. Results: The average age was 69.7±10.3 years; 66.7% were male. All patients had left ventricular hypertrophy and 83.3% had heart failure. Three patients (50%) showed grade 2-3 uptake; among them, two (33.3%) met criteria for noninvasive ATTR diagnosis (grade 3, positive SPECT, and negative monoclonal screening), with H/CL values above diagnostic cutoffs. One grade 2 case had an IgG kappa monoclonal component and was classified as inconclusive. Three patients (50%) had grade 1 uptake, considered equivocal, with H/CL values below diagnostic thresholds. SPECT was essential to confirm true myocardial uptake and avoid overinterpretation in borderline cases. Conclusions: Tc-PYP is feasible in our setting and allows for appropriate classification of patients with suspected ATTR.
No takes yet. Share an insight, caveat, or question.
Orihuela et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: